WebMar 26, 2024 · Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, nationality, national or ethnic origin, civil status, age, citizenship status, membership of the Traveler community, sexual orientation, disability, genetic information, … Web12 hours ago · Century Aggregates has been trucking gravel, rock and sand from a site in Tarrytown where Regeneron, a biotech company, broke ground in June on a $1.8 billion, 724,000-square-foot research and manufacturing facility, ... construction of a 4,400-square-foot dog-training facility, ...
Working at Regeneron Pharmaceuticals - Niche
WebRegeneron’s current therapies help millions worldwide with ocular, cardiovascular, and inflammatory diseases as well as cancer, allergic conditions, and pain. EYP’s master plan ensures they can continue building their legacy of wellness and pushing the boundaries of science to make life-changing medicines. 1,000,000 GSF. WebMar 29, 2024 · The position is located in Tarrytown, but occasional travel (up to 25%) to project sites may be required. A typical day might include: Develops well-conceived and timely project plans that outline and map the overall project process and breaks critical focus areas that provide detailed, well informed roadmaps and risk aversion planning brenda richie fight
Senior Project Manager - Facilities Construction - Regeneron ...
WebJul 15, 2024 · By Liz Young. – Staff Reporter, New York Business Journal. Jul 15, 2024. Regeneron Pharmaceuticals Inc. plans to invest about $1.8 billion to expand its Tarrytown … WebApr 14, 2024 · Senior Statistical Programmer. Job in Tarrytown - Westchester County - NY New York - USA , 10591. Listing for: Regeneron Pharmaceuticals. Full Time position. Listed on 2024-04-14. Job specializations: Engineering. WebAug 24, 2024 · TARRYTOWN, N.Y., Aug. 24, 2024 /PRNewswire/ -- Phase 3 trials in wet AMD and diabetic macular edema fully recruited, with results expected in the second half of 2024. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its … counterbore drills